CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board
September 19 2018 - 4:30PM
Business Wire
Regulatory News:
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies
based on gene-edited CAR T-cells (UCART), today announced that
Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at
Children's Hospital of Philadelphia and Chief of the Section of
Cellular Therapy and Transplant at the Children's Hospital of
Philadelphia (CHOP) joined the Company’s Clinical Advisory Board
(CAB).
Dr. Grupp is a world-renowned pediatric oncologist and cancer
researcher who initiated the first pediatric CAR T-cell trial for
acute lymphoblastic leukemia at CHOP in 2012. He also delivered CAR
T-cell therapy to the first pediatric patient in the world, paving
the way for clinical development of engineered T-cell therapies.
Dr. Grupp then led the first multicenter global study of Kymriah®,
which became the first CAR-T therapy to receive approval by the
U.S. Food and Drug Administration (FDA).
“Dr. Grupp is one of the true pioneers that have marked the
history of CAR T-cell therapies whose decades of work and
distinction as a true visionary will continue to shape and inform
the future of these transformative therapies in the service of
pediatric patients suffering from cancer,” said Dr. André Choulika,
Cellectis CEO. “His experience in pediatric oncology and
groundbreaking work in CAR-T therapy will be an enormous asset for
Cellectis’ CAB, and his firm belief in Cellectis’ unique approach
lends additional credence to our innovative work developing
allogeneic CAR-T therapies.”
“Over the course of my career, I have devoted a great deal of
attention to both autologous and allogeneic cellular therapies for
pediatric cancer patients, and I believe universal CAR-T products
can change the paradigm of cancer treatment and address urgent
unmet medical needs. I have great hopes that allogeneic CAR-T
therapy can open up treatment options for patients who don’t have
enough T-cells to undergo an autologous CAR-T therapy, or who live
in regions where the technology is not available,” added Dr. Grupp.
“My mission throughout my career has been to change the standard of
care for pediatric patients who are battling difficult cancers, so
joining Cellectis’ CAB presents a unique opportunity to
strategically guide and advance the development of these lifesaving
therapies.”
Dr. Grupp is Chief of the Cell Therapy and Transplant Section,
Director of the Cancer Immunotherapy Program, Director of
Translational Research for the Center for Childhood Cancer Research
and Medical Director of the Stem Cell Laboratory at CHOP, as well
as an attending physician in the Cancer Center at CHOP, where he
has worked for more than two decades. Dr. Grupp completed a
pediatric residency at Boston Children’s Hospital, and a pediatric
hematology/oncology fellowship at Dana-Farber Cancer Institute and
Children’s Hospital. He also completed a research fellowship in
immunology at Brigham and Women’s Hospital.
Dr. Grupp has published numerous papers on various therapies for
the treatment of children with cancers, including CAR T-cell
therapies, and has been honored by numerous prestigious
organizations for his work, including the American Society of
Pediatric Hematology / Oncology and American Pediatric Society.
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused
on developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 18 years of
expertise in gene editing – built on its flagship TALEN® technology
and pioneering electroporation system PulseAgile – Cellectis uses
the power of the immune system to target and eradicate cancer
cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq (ticker: CLLS) and on Euronext
Growth (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by Cellectis.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Further information on the risk
factors that may affect company business and financial performance
is included in Cellectis’ Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2017 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180919005779/en/
Media:Jennifer MooreVP of Communications,
917-580-1088media@cellectis.comorCaitlin KasunichKCSA Strategic
Communications, 212-896-1241ckasunich@kcsa.comorIR:Simon
HarnestVP of Corporate Strategy and Finance,
646-385-9008simon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024